Clinical Toxicology, volume 56, issue 12, pages 1200-1203
Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed
Théo Willeman
1
,
Raphael Marlu
2
,
Holger Böhle
3
,
Gilles Francony
3
,
Jean-François Jourdil
1
,
Xavier Fonrose
1
,
Françoise Stanke-Labesque
1, 4
Publication type: Journal Article
Publication date: 2018-06-11
Journal:
Clinical Toxicology
scimago Q1
SJR: 0.956
CiteScore: 5.7
Impact factor: 3
ISSN: 15563650, 15569519, 00099309
General Medicine
Toxicology
Abstract
Ticagrelor is a direct and reversible competitive antagonist of the P2Y12 receptor and inhibits platelet activation. Although adverse bleeding is common, fatal intoxication has never been documented.A 47-year-old man died from a severe cerebral hemorrhage secondary to a fall and cranial trauma 4 d after the massive intake of ticagrelor. Iterative platelet transfusions did not improve his condition. Toxicological analyses by liquid chromatography tandem mass spectrometry (LC-MS/MS) revealed high plasma concentrations of ticagrelor (3343 µg/L) and its active metabolite AR-C124910XX (656 µg/L) 10 h after intake. The approximate ingested dose was extrapolated to 1677 mg. Assessment of ADP-induced platelet aggregation and platelet Vasodilator Stimulated Phosphoprotein phosphorylation (VASP), 2 and 3 d after admission, respectively, showed the persistence of platelet inhibition.To the best of our knowledge, no prior fatal cases have been reported and documented with both ticagrelor and AR-C124910XX concentrations. Our findings highlight the need for a specific antidote to manage such complications resulting from ticagrelor overdose.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.